Medical Central Oxygen Supply System MarketSize, Share & Industry Analysis, 2026-2034By Product TypeBy ApplicationBy End-userBy System TypeBy Component

A medical central oxygen supply system delivers medical-grade oxygen from a single source, whether a liquid oxygen tank, an on-site pressure swing adsorption generator, or a cylinder manifold, through a piped distribution network to multiple points of use within a healthcare facility. The category covers the generation or storage equipment, the compressors and vacuum components that maintain pressure and flow, and the valves, regulators and outlet fittings that connect the network to bedside and procedure-room terminals. Buyers are hospitals, ambulatory surgical centers and diagnostic facilities that need continuous, code-compliant oxygen delivery instead of relying on individual portable cylinders.

The global medical central oxygen supply system market is valued at USD 440 million in 2025 and is set to reach USD 966 million by 2034, a compound annual growth rate of 9.14% across the 2026-2034 forecast period. The study tracks the market across USD 280 million in 2020, USD 400 million in 2024, USD 480 million in 2026 and USD 682 million in 2030.

20% of 2025 revenue sits in Cylinders, worth USD 88 million and rising to USD 154.6 million at 16% by 2034, the largest product type line in both years. Growth is fastest in Compressors at 14.03% and slowest in Cylinders at 6.43%. The lines gaining share are Compressors, Vacuum Systems and Regulator. Pure Medical Gases, Medical Gas Mixtures, Cylinders, Hose Assemblies and Valves, Masks and Others lose share without losing revenue.

The application split puts Therapeutic first, at USD 343.2 million and 78% of revenue in 2025, rising to USD 734.2 million and 76% in 2034. Others grows faster at 10.75% against 8.82%, moving from 7% of revenue to 7.99% by 2034. It cuts the same total as the product type axis from a different commercial angle, so revenue does not add across the two.

The regional order runs from Asia Pacific at 30% of 2025 revenue down to Latin America at 8%. Asia Pacific is worth USD 132 million in 2025 and USD 328.4 million in 2034; North America, second at 28%, moves from USD 123.2 million to USD 231.8 million. Share shifts toward Asia Pacific, Latin America and Middle East and Africa over the forecast period, so the regional split repays a close reading.

The 2025 total is triangulated from published sources and category proxies, with no independently sourced count behind it. Segment, regional and country splits are estimated on the same basis, which bounds the precision of the figures above. Coverage runs to five regions, nine product type lines and five segmentation axes across a fifteen-year window.

• A forecast-period rate of 9.14% takes the market from USD 440 million in 2025 to USD 966 million in 2034, against 9.47% recorded over the 2020-2025 historical period.
• Cylinders is the largest product type line at USD 88 million in 2025, a 20% share, reaching USD 154.6 million and 16% of revenue by 2034.
• At 14.03%, Compressors grows faster than any other product type line, moving from USD 70.4 million and 16% of revenue in 2025 to USD 231.8 million and 24% in 2034.
• The bull case puts 2034 revenue at USD 1050 million and the bear case at USD 866 million, either side of the USD 966 million base case, each with its own stated assumption in the full report.
• The largest region is Asia Pacific, generating USD 132 million in 2025 (30% of the global total) and USD 328.4 million by 2034, ahead of North America at 28%.
• China accounts for 38% of Asia Pacific in the base year, worth USD 50.2 million in 2025 and reaching USD 111.7 million by 2034, the worked country example carried through that region's chapters.
• Every line on all five segmentation axes and in each of the five regions carries its own revenue, share and growth rate for all fifteen years, 2020 through 2034, on a 2025 base.

The global medical central oxygen supply system market is shaped over 2026-2034 by three measurable movements: a change in the product type mix, a shift in where revenue sits geographically, and the 9.14% rate carrying the total.

Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.

Compressors outpaces Cylinders. 14.03% against 6.43%: that gap, between Compressors and Cylinders, is the largest on the product type axis. Shares follow: 16% to 24% for Compressors, 20% to 16% for Cylinders. Neither contracts: USD 70.4 million becomes USD 231.8 million, USD 88 million becomes USD 154.6 million. What the spread decides is which of them a supplier's revenue is exposed to.

Regional weight shifts toward Asia Pacific, Latin America and Middle East and Africa. Asia Pacific moves from 30% of revenue in 2025 to 34% in 2034, worth USD 132 million rising to USD 328.4 million; Latin America moves from 8% of revenue in 2025 to 9% in 2034, worth USD 35.2 million rising to USD 86.9 million; Middle East and Africa moves from 10% of revenue in 2025 to 13% in 2034, worth USD 44 million rising to USD 125.7 million. The offsetting side is North America at 28% moving to 24%, Europe at 24% moving to 20%, none of which contracts. That makes the regional split worth reading directly instead of scaling from the global rate: the same market rate produces different outcomes depending on where a supplier's revenue sits.

Growth compounds at 9.14% without a step change. Year by year the total runs USD 280 million in 2020, USD 400 million in 2024, USD 440 million in 2025, USD 480 million in 2026, USD 682 million in 2030 and USD 966 million in 2034. The forecast rate of 9.14% sits against 9.47% over the historical period, so the projection extends an observed trend instead of proposing a new one. A plan built on this market is therefore a plan about capturing a share of steady expansion, which is decided on the product type and regional axes, not by the headline rate.

The fastest line decides the blended rate

Separate the 9.14% into its parts and three show up: an already-large base compounding, the product type mix moving toward its faster lines, and regional growth landing unevenly.

Downside case: USD 866 million by 2034, against USD 966 million in the base case

Where the forecast could be beaten

Concentration on the product type axis

28% of the global medical central oxygen supply system market sits in North America in 2025, worth USD 123.2 million and reaches USD 231.8 million by 2034. It is a leading region on this axis, second by revenue throughout the period.

By 2034 the share stands at 24%, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

The product type mix reported at global level applies here, with Cylinders the largest line at 20% of 2025 revenue and Compressors the fastest-growing at 14.03%. Revenue for North America is broken out by every segmentation axis and by country in the full report.

85% of North America's base-year revenue comes from the United States; USD 104.7 million, rising to USD 197 million by 2034. 85% of the region in 2025 means the regional figures are, in practice, a view of this market with others attached. Set against USD 123.2 million and USD 231.8 million for the region, it is why this market, and not a smaller one, is the one reported in full.

the United States buys along the same lines as the market globally; Cylinders first at 20% of 2025 revenue and 16% in 2034, Compressors fastest at 14.03% on a share moving from 16% to 24%. With 85% of North America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. The United States carries its own product type breakdown in the full report.

Central oxygen supply systems installed in hospitals fall under the Food and Drug Administration as medical devices, since the piping, manifolds, alarms, and outlets that deliver medical gas to patient care areas are regulated components rather than mere plumbing. Manufacturers must classify the system correctly and clear it through the applicable premarket pathway before sale, then meet FDA quality system requirements covering design controls, manufacturing, and labelling. Facility-level installation is additionally governed by NFPA standards for medical gas and vacuum systems, which set requirements for source equipment, distribution piping, alarm systems, and verification testing, and hospitals must maintain compliance with these standards to satisfy accreditation and life-safety inspections. Oxygen itself is treated as a prescription drug subject to current good manufacturing practice, so the purity and delivery chain are both regulated in parallel.

Competition in the United States runs between the suppliers this study tracks: PCI Gases, Oxyplus Technologies (NOVAIR), Oxymat A/S, Oxair, On Site Gas Systems, OGSI and Chart Industries. Volume sits in Cylinders at 20% of 2025 revenue; movement sits in Compressors at 14.03% growth. Country-level shares and positioning per company sit in the full report.

Within North America, Canada accounts for 13% of regional revenue and 3.6% of the global total, worth USD 16 million in 2025 and USD 30.1 million by 2034.

USD 105.6 million of 2025 revenue is generated in Europe, 24% of the global medical central oxygen supply system market rising to USD 193.2 million in 2034. That makes it the third-largest region covered, in 2025 and again in 2034.

Its share moves to 20% by 2034, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.

The product type mix reported at global level applies here, with Cylinders the largest line at 20% of 2025 revenue and Compressors the fastest-growing at 14.03%. Per-axis and per-country detail for Europe sits in the full report.

30% of Europe's base-year revenue comes from Germany; USD 31.7 million, rising to USD 58 million by 2034. Its 30% of base-year regional revenue leads the region, though enough sits elsewhere that Europe is not a proxy for it. Regional revenue of USD 105.6 million in 2025 and USD 193.2 million in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Composition here matches the global split: the largest line is Cylinders at 20% of 2025 revenue, easing to 16% by 2034, and the fastest is Compressors at 14.03%, from 16% to 24%. Its 30% weight in Europe means those movements carry straight into the regional totals. Germany carries its own product type breakdown in the full report.

Central oxygen supply systems in Germany are regulated as medical devices under the EU Medical Device Regulation, which governs the manifolds, pipeline networks, alarm units, and terminal outlets that make up the installed system. A supplier must hold a valid conformity assessment, affix CE marking, and maintain technical documentation demonstrating conformity with the harmonised standard covering pipeline systems for medical gases before the system can be placed on the market or put into service. Installation and ongoing operation are further governed by German medical device operator regulations, which impose maintenance, testing, and record-keeping duties on the operating hospital. Medicinal oxygen supplied through the system is separately regulated as a pharmaceutical product, so its manufacture and distribution fall under German pharmaceutical law and are overseen by the competent federal authority.

Competition in Germany runs between the suppliers this study tracks: PCI Gases, Oxyplus Technologies (NOVAIR), Oxymat A/S, Oxair, On Site Gas Systems, OGSI and Chart Industries. Cylinders, at 20% of 2025 revenue, is where the volume sits, and Compressors, growing at 14.03%, is where position changes hands over the forecast period. The commercial size of that position is USD 105.6 million in 2025, moving to USD 193.2 million by 2034 across the forecast period.

The United Kingdom is sized at USD 23.2 million in 2025, rising to USD 42.5 million by 2034; 5.3% of global revenue and 22% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

Within Europe, France accounts for 16% of regional revenue and 3.8% of the global total, worth USD 16.9 million in 2025 and USD 30.9 million by 2034.

30% of the global medical central oxygen supply system market sits in Asia Pacific in 2025, worth USD 132 million on the way to USD 328.4 million by 2034. It is a leading region on this axis, first by revenue throughout the period.

Share climbs to 34% by 2034, so the region grows faster than the market's 9.14% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.

Segment composition follows the global pattern: Cylinders largest at 20% of 2025 revenue, Compressors fastest at 14.03%. The full report breaks Asia Pacific out along every axis and by country.

China is the largest market within Asia Pacific, generating USD 50.2 million in 2025 and projected to reach USD 111.7 million by 2034. At 38% of the region in 2025 it leads, but a majority of Asia Pacific's revenue is generated in other markets. Set against USD 132 million and USD 328.4 million for the region, it is why this market, and not a smaller one, is the one reported in full.

China buys along the same lines as the market globally; Cylinders first at 20% of 2025 revenue and 16% in 2034, Compressors fastest at 14.03% on a share moving from 16% to 24%. Since 38% of Asia Pacific's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Per-product type revenue for China appears on its own in the full report.

China regulates central oxygen supply systems as medical devices under the National Medical Products Administration, which assigns a risk classification to the pipeline network, manifold, and alarm components and requires registration before the system may be marketed or installed. Registration requires the manufacturer to submit technical and clinical evidence appropriate to the assigned class, and the finished system must conform to national standards covering medical gas pipeline installations, including provisions for pressure, alarm function, and terminal unit design. Manufacturing facilities are subject to inspection against China's medical device quality management regulations, and imported systems must additionally go through a registered in-country agent. Oxygen gas supplied through the system is regulated separately as a pharmaceutical product, placing its production and distribution under pharmaceutical administration rules enforced alongside the device framework.

In China the field is PCI Gases, Oxyplus Technologies (NOVAIR), Oxymat A/S, Oxair, On Site Gas Systems, OGSI and Chart Industries. Volume sits in Cylinders at 20% of 2025 revenue; movement sits in Compressors at 14.03% growth. A supplier weighted toward Asia Pacific is competing over a base of USD 132 million in 2025, reaching USD 328.4 million by 2034 on the trajectory this study models.

India is sized at USD 29 million in 2025, rising to USD 92 million by 2034; 6.6% of global revenue and 22% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.

Within Asia Pacific, Japan accounts for 15% of regional revenue and 4.5% of the global total, worth USD 19.8 million in 2025 and USD 39.4 million by 2034.

USD 35.2 million of 2025 revenue is generated in Latin America, 8% of the global medical central oxygen supply system market and reaches USD 86.9 million by 2034. Among the five regions it ranks fifth by revenue in both years.

Its share rises to 9% over the forecast period, on growth above the market's own 9.14%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.

The product type mix reported at global level applies here, with Cylinders the largest line at 20% of 2025 revenue and Compressors the fastest-growing at 14.03%. The full report breaks Latin America out along every axis and by country.

The largest single market in Latin America is Brazil, at USD 15.8 million in 2025 and USD 39.1 million in 2034. At 44.9% of the region in 2025 it leads, but a majority of Latin America's revenue is generated in other markets. Regional revenue of USD 35.2 million in 2025 and USD 86.9 million in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Demand in Brazil follows the product type mix reported at global level: Cylinders is the largest line at 20% of 2025 revenue, moving to 16% by 2034, while Compressors grows fastest at 14.03% and takes its share from 16% to 24%. Since 44.9% of Latin America's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. The full report reports Brazil by product type separately.

Central oxygen supply systems in Brazil are regulated by ANVISA, the national health surveillance agency, which classifies the pipeline, manifold, alarm, and outlet components as medical devices requiring registration before commercial distribution or installation. Registration requires evidence of conformity with applicable technical standards for medical gas pipeline systems, and manufacturing sites are subject to good manufacturing practice certification issued or recognised by ANVISA. Facilities operating these systems must additionally comply with health surveillance rules governing hospital infrastructure, including periodic testing and maintenance of piping and alarm integrity to retain operating authorisation. Medicinal oxygen delivered through the system is regulated as a pharmaceutical product in its own right, so the gas supply chain sits under separate pharmaceutical oversight even where the physical delivery system shares the same installation.

In Brazil the field is PCI Gases, Oxyplus Technologies (NOVAIR), Oxymat A/S, Oxair, On Site Gas Systems, OGSI and Chart Industries. The commercially relevant division is 20% of 2025 revenue in Cylinders, where the volume is, against 14.03% growth in Compressors, where share moves. The commercial size of that position is USD 35.2 million in 2025, moving to USD 86.9 million by 2034 across the forecast period.

2.4% of global revenue is generated in Mexico; USD 10.6 million in 2025, reaching USD 26.1 million in 2034, and 30.1% of Latin America.

USD 44 million of 2025 revenue is generated in Middle East and Africa, 10% of the global medical central oxygen supply system market rising to USD 125.7 million in 2034. That makes it the fourth-largest region covered, in 2025 and again in 2034.

Its share rises to 13% over the forecast period, on growth above the market's own 9.14%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.

Within the region the product type split tracks the global one; 20% of 2025 revenue in Cylinders, fastest growth of 14.03% in Compressors. Middle East and Africa is reported axis by axis and country by country in the full study.

The largest single market in Middle East and Africa is Saudi Arabia, at USD 12.3 million in 2025 and USD 35.2 million in 2034. At 28% of the region in 2025 it leads, but a majority of Middle East and Africa's revenue is generated in other markets. Against regional totals of USD 44 million in 2025 and USD 125.7 million in 2034, it is the country the full report breaks out in detail.

Saudi Arabia buys along the same lines as the market globally; Cylinders first at 20% of 2025 revenue and 16% in 2034, Compressors fastest at 14.03% on a share moving from 16% to 24%. Because the country carries 28% of Middle East and Africa, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Per-product type revenue for Saudi Arabia appears on its own in the full report.

In Saudi Arabia, central oxygen supply systems are regulated as medical devices by the Saudi Food and Drug Authority, which requires the manufacturer or an authorised local representative to register the system before it can be marketed, imported, or installed in a healthcare facility. Registration follows a risk-based classification route and requires technical documentation showing conformity with recognised international standards for medical gas pipeline systems, alarm units, and terminal outlets. Installed systems are also subject to facility licensing requirements administered through the Ministry of Health, which reviews medical gas infrastructure as part of hospital accreditation and ongoing inspection. Medicinal oxygen supplied through the pipeline is treated as a pharmaceutical product and regulated separately from the physical delivery hardware, consistent with the dual device-and-drug oversight seen in other major markets.

Competition in Saudi Arabia runs between the suppliers this study tracks: PCI Gases, Oxyplus Technologies (NOVAIR), Oxymat A/S, Oxair, On Site Gas Systems, OGSI and Chart Industries. Cylinders, at 20% of 2025 revenue, is where the volume sits, and Compressors, growing at 14.03%, is where position changes hands over the forecast period. The commercial size of that position is USD 44 million in 2025, moving to USD 125.7 million by 2034 across the forecast period.

1.8% of global revenue is generated in South Africa; USD 7.9 million in 2025, reaching USD 22.6 million in 2034, and 18% of Middle East and Africa.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Product Type, Application, End-User, System Type, Component, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.